Private Payors Curtailing Excessive Diagnostic Imaging – Health Affairs Study
This article was originally published in The Gray Sheet
Executive Summary
Private insurers are returning to cost-containment strategies, including limiting superfluous diagnostic tests, in the face of rising healthcare costs coupled with an economic slowdown, an Aug. 11 Health Affairs web exclusive maintains
You may also be interested in...
MedPAC To Further Analyze Diagnostic Imaging Purchasing Strategies
The Medicare Payment Advisory Commission plans to continue exploring whether Medicare should do more to emulate private insurers' strategies for controlling the growth of imaging services during the next year
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.